The Governments of Canada and Manitoba are investing $400,000 to help survey Manitobans about their opinions, preferences and experiences with food and health which will lead to food development and creating a healthier future for Manitobans
News & Media
Cangene returned to profitability in the second quarter with revenue up compared to the year before
Provincial and Federal Governments Commit More Than $406,000 to Agri-Health Research Network in Manitoba
The Governments of Canada and Manitoba are committing $406,000 in funding in 2010/11 to the Manitoba Agri-Health Research Network Inc. (MAHRN) to support the further research, development and commercialization of projects that identify links between food
The Governments of Canada and Manitoba announced they are contributing to a $10 million strategic initiative to enhance the capacity of the province’s medical device industry to develop and commercialize specialized joint replacement technology
DiaMedica announced antihypertensive results with its lead monoclonal antibody DM-204. Consistent and significant blood pressure lowering results are observed with DM-204 in all animals and the lower blood pressure occurred for the duration of the study
IMRIS Inc. announced the sale of IMRISneuro to the University Hospital Tübingen, located in Tübingen, Germany.
AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment
Valeant Pharmaceuticals International, Inc. announces fourth quarter financial results for 2010.
Science Applications International Corporation (SAIC) announced it was awarded a contract extension by the National Aeronautics and Space Administration (NASA) for the Unified NASA Information Technology Services (UNITeS) contract
Kane Biotech has been named one of the top ten companies in the biotech industry by Fast Company in its annual list of the world’s “Most Innovative Companies.
The governments of Canada and Manitoba announced $2.6 million for the expansion of the Food Development Centre (FDC). Manitoba Agriculture, Food and Rural Initiatives (MAFRI) Minister Stan Struthers and Federal Member of Parliament Candice Hoeppner (Porta
The Manitoba government will assist the Pan Am Clinic in working with Echometrix LLC to assess the use of innovative ultrasound technology to diagnose and treat soft-tissue injuries and conditions, Innovation, Energy and Mines Minister Dave Chomiak announ
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent (LOI) with PreMD Inc. to license the exclusive world
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company’s Research and Development (R&D) team has made contributions to two new scie
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at
Medical technology company IMRIS Inc. (TSX:IM) booked its first-ever positive results as revenues more than tripled in the fourth quarter.
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled “Compositions and methods for enzymatic detac
GVI Clinical Development Solutions (GVI-CDS), an innovative CRO focused on quality, timeliness and cost effective services, is pleased to announce that Douglas A. Elliott and Sandra Reis have joined GVI-CDS.
Miraculins Announces Partnership with Inverness Medical Innovations to Develop a Diagnostic Test for Preeclampsia
Agreement Includes Fee From Inverness to Acquire Exclusive Option to License Worldwide Rights.
DiaMedica Inc. (TSX-V:DMA) (“Diamedica”), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding sh
Drug firm concentrates all its work in Manitoba